Privium Fund Management B.V. Cuts Position in Roivant Sciences Ltd. (NASDAQ:ROIV)

Privium Fund Management B.V. reduced its stake in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) by 55.5% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 215,506 shares of the company’s stock after selling 268,994 shares during the quarter. Roivant Sciences makes up 0.6% of Privium Fund Management B.V.’s holdings, making the stock its 26th largest position. Privium Fund Management B.V.’s holdings in Roivant Sciences were worth $2,549,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently added to or reduced their stakes in the company. US Bancorp DE lifted its position in shares of Roivant Sciences by 146.5% during the third quarter. US Bancorp DE now owns 3,278 shares of the company’s stock valued at $38,000 after buying an additional 1,948 shares during the last quarter. GAMMA Investing LLC lifted its position in Roivant Sciences by 57.0% during the fourth quarter. GAMMA Investing LLC now owns 3,548 shares of the company’s stock valued at $42,000 after acquiring an additional 1,288 shares during the last quarter. PNC Financial Services Group Inc. boosted its stake in Roivant Sciences by 27.0% in the fourth quarter. PNC Financial Services Group Inc. now owns 7,079 shares of the company’s stock valued at $84,000 after acquiring an additional 1,507 shares in the last quarter. Quarry LP grew its holdings in Roivant Sciences by 50.0% in the third quarter. Quarry LP now owns 7,500 shares of the company’s stock worth $87,000 after purchasing an additional 2,500 shares during the last quarter. Finally, Blue Trust Inc. increased its position in shares of Roivant Sciences by 550.1% during the fourth quarter. Blue Trust Inc. now owns 7,879 shares of the company’s stock worth $91,000 after purchasing an additional 6,667 shares in the last quarter. Institutional investors own 64.76% of the company’s stock.

Insider Transactions at Roivant Sciences

In related news, Director Sciences Ltd. Roivant bought 16,845,010 shares of the company’s stock in a transaction that occurred on Monday, January 13th. The shares were purchased at an average cost of $20.00 per share, with a total value of $336,900,200.00. Following the completion of the acquisition, the director now directly owns 96,650,341 shares in the company, valued at approximately $1,933,006,820. The trade was a 21.11 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CIO Mayukh Sukhatme sold 689,495 shares of Roivant Sciences stock in a transaction that occurred on Thursday, December 26th. The shares were sold at an average price of $12.01, for a total value of $8,280,834.95. Following the transaction, the executive now owns 18,836,547 shares of the company’s stock, valued at approximately $226,226,929.47. This represents a 3.53 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 1,975,586 shares of company stock worth $22,640,661 over the last 90 days. 7.90% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several brokerages recently weighed in on ROIV. Cantor Fitzgerald upgraded Roivant Sciences to a “strong-buy” rating in a research note on Tuesday, March 4th. HC Wainwright restated a “buy” rating and set a $18.00 price target on shares of Roivant Sciences in a research note on Tuesday, February 11th. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $18.08.

Roivant Sciences Stock Performance

Roivant Sciences stock opened at $10.71 on Wednesday. The business’s 50-day simple moving average is $10.78 and its two-hundred day simple moving average is $11.48. The company has a market cap of $7.64 billion, a PE ratio of -71.40 and a beta of 1.26. Roivant Sciences Ltd. has a fifty-two week low of $9.76 and a fifty-two week high of $13.06.

Roivant Sciences (NASDAQ:ROIV) last issued its earnings results on Monday, February 10th. The company reported ($0.20) EPS for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative return on equity of 14.05% and a negative net margin of 119.54%. As a group, analysts predict that Roivant Sciences Ltd. will post -0.92 EPS for the current fiscal year.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.